Source: Virtual Congress 2021 – Pulmonary rehabilitation in the COVID-19 era



Rating:

Share or cite this content

Citations should be made in the following way:
L. Konopkina (Dniepropetrovsk, Ukraine), L. Botvinikova (Dniepropetrovsk, Ukraine), O. Shchudro (Dniepropetrovsk, Ukraine), O. Myronenko (Dniepropetrovsk, Ukraine), O. Plekhanova (Dniepropetrovsk, Ukraine). The assessment of the metabolic dysfunction in patients (pts) after COVID-19 pneumonia. 603

Member's Comments

No comment yet.

Related content which might interest you: Mental disorders in patients (pts) with COVID-19 pneumonia:comparison with COPD exacerbation Source: Virtual Congress 2021 – Long COVID - 19 Year: 2021 The dynamics of dyspnea in patients (pts) with pneumonia on the background of SARS-CoV2 infection Source: Virtual Congress 2021 – Respiratory failure in COVID19 and beyond Year: 2021 Myocardial dysfunction in patients (pts) after severe coronavirus disease (COVID-19) Source: Virtual Congress 2021 – Imaging in COVID-19 Year: 2021 Evaluation of Behcet‘s disease patients who admitted with pulmonary symptoms (analysis of 14 cases) Source: Annual Congress 2007 - Miscellaneous interstitial lung diseases related to systemic and other diseases Year: 2007 Is it connection between systemic inflammation and risk of thrombotic disorders (by Padua scale) in hospitalized patients with community-acquired pneumonia (CAP)? Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection Year: 2018 Endothelial dysfunction and its corrections in patients with severe community-aquired pneumonia (CAP) Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections Year: 2020 Impact of systemic inflammation on frequency and severityof mental disorders in COPD patients (pts) Source: Virtual Congress 2020 – Clinical and functional evaluation of COPD Year: 2020 Does the condition of chronic obstructive pumonary disease (COPD) have a prognostic benefit in patients with community-acquired pneumonia (CAP)? Source: Eur Respir J 2003; 22: Suppl. 45, 338s Year: 2003 Detection of liver function in patients with severe community-acquired pneumonia (CAP) Source: Eur Respir J 2002; 20: Suppl. 38, 15s Year: 2002 The estimation of respiratory muscles (RM) status by echodensitometry in male patients with acute exacerbation of COPD (AECOPD) Source: Annual Congress 2010 - Interaction between respiratory and peripheral muscles Year: 2010 The influence of co-morbidity on the outcome of non-invasive ventilatory support in patients with acute respiratory failure (ARF) in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 277s Year: 2002 Metabolic syndrome (MS) in COPD patients entering pulmonary rehabilitation (PR) Source: Annual Congress 2008 - Assessing profiles of rehabilitation candidates Year: 2008 Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 Diagnosis on community-acquired pneumonia (CAP) in patients with congestive heart failure (CHF) Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017 Incorporating patients with chronic heart failure (CHF) into pulmonary rehabilitation (PR): a propensity matched analysis Source: Virtual Congress 2020 – Optimising the benefits of pulmonary rehabilitation Year: 2020 Definition of severity and the reasons for hospitalization (RH) in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 641s Year: 2005 Incidence of severe sepsis as a cause of clinical failure in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2007; 30: Suppl. 51, 42s Year: 2007 The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP) Source: International Congress 2014 – Clinical presentations Year: 2014 Lymphocyte-to-Monocyte ratio (LMR) and Platelet-to-lymphocyte (PLR) ratio levels as a predictors of lung failure in severe Covid-19 pneumonia patients (pts) Source: Virtual Congress 2021 – COVID - 19: lessons learned Year: 2021 Cardiac diseases in patients with community acquired pneumonia (CAP) Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections Year: 2012